Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Shares, No Par Value
-
Shares outstanding
-
28,495,649
-
Number of holders
-
2
-
Total 13F shares, excl. options
-
833,802
-
Shares change
-
-90,983,584
-
Total reported value, excl. options
-
$2,716,547
-
Value change
-
-$68,395,020
-
Number of sells
-
-44
-
Price
-
$3.20
Significant Holders of Oncocyte Corporation - Common Shares, No Par Value (OCX) as of Q3 2023
45 filings reported holding OCX - Oncocyte Corporation - Common Shares, No Par Value as of Q3 2023.
Oncocyte Corporation - Common Shares, No Par Value (OCX) has 2 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 833,802 shares
of 28,495,649 outstanding shares and own 2.9% of the company stock.
Largest 10 shareholders include AWM Investment Company, Inc. (719,282 shares), Defender Capital, LLC. (114,520 shares), Lindbrook Capital, LLC (0 shares), LEE DANNER & BASS INC (0 shares), LEVIN CAPITAL STRATEGIES, L.P. (0 shares), UBS Group AG (0 shares), RHUMBLINE ADVISERS (0 shares), MEEDER ASSET MANAGEMENT INC (0 shares), JPMORGAN CHASE & CO (0 shares), and RENAISSANCE TECHNOLOGIES LLC (0 shares).
This table shows the top 2 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.